Lacosamid Fresenius Kabi

Lacosamide, the active ingredient in Lacosamid Fresenius Kabi, is an anticonvulsant presented as an intravenous solution for intravenous use. It is used to treat partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamid Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lacosamide is an antiepileptic drug that modulates neuronal excitability in seizure disorders.

Partial‑onset seizures: Reduces seizure frequency when used as adjunctive therapy. Epilepsy (focal epilepsy): Provides seizure control in patients with refractory focal seizures. Adjunctive therapy: Enhances overall seizure management when combined with other antiepileptic medications.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Diplopia (double vision) - Somnolence

Serious or Rare Side Effects: - Cardiac conduction abnormalities (PR‑interval prolongation) - Atrioventricular block - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Acute pancreatitis - Severe hypersensitivity reactions

When using Lacosamid Fresenius Kabi, consider the following safety measures.

Renal impairment: Adjust dosing in patients with reduced renal function. Hepatic impairment: Monitor liver function and consider dose modification. Cardiac conduction disorders: Avoid in patients with pre‑existing PR‑interval prolongation. Concomitant antiepileptics: Assess for additive CNS depression. Pregnancy and lactation: Use only if the potential benefit justifies the potential risk, as safety data are limited. Store at ambient temperature: Keep in original packaging, protect from moisture and direct sunlight.

Lacosamide may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Co‑administration with other sodium‑channel blockers that affect cardiac conduction (e.g., carbamazepine, phenytoin). - Drugs that significantly prolong PR interval (e.g., certain antiarrhythmics).

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole) may increase lacosamide levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce lacosamide exposure. - CNS depressants (e.g., benzodiazepines, alcohol) can enhance sedation. - Anticoagulants may require monitoring of coagulation parameters.